David-Axel Laplaud

23PUBLICATIONS
177CO-AUTHORS
Gene and molecular therapyMedical microbiology not elsewhere classifiedRegenerative medicine (incl. stem cells)Predictive and prognostic markersOptometry
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jun 02, 2026
A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

|May 29, 2026
Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

|May 22, 2026
French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.

|May 14, 2026
PRIMUS: a precision medicine platform reusing clinical trials and registry data to support treatment selection in multiple sclerosis.

|May 05, 2026
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.

|Apr 01, 2026
Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.

Apolline Tournier, Antoine Gavoille, Julie Pique

Pageof 4

Frequent Collaborators

12 joint publications

Sandra Vukusic

11 joint publications

Eric Thouvenot

10 joint publications

Jonathan Ciron

10 joint publications

Christine Lebrun-Frenay